当前蛋白身份:Q0TR53 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
2J62 Structure of a bacterial O-glcnacase in complex with glcnacstatin 提交 2006-09-22 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–624(594 aa) 片段:RESIDUES 31-624
链 B 31–624(594 aa) 片段:RESIDUES 31-624
未记录 CL CHLORIDE ION × 4 GSZ N-[(5R,6R,7R,8S)-6,7-DIHYDROXY-5-(HYDROXYMETHYL)-2-(2-PHENYLETHYL)-1,5,6,7,8,8A-HEXAHYDROIMIDAZO[1,2-A]PYRIDIN-8-YL]-2-METHYLPROPANAMIDE × 2 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.26 Å R-free 0.219
2JH2 X-ray crystal structure of a cohesin-like module from Clostridium perfringens 提交 2007-02-19 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 768–909(142 aa) 片段:RESIDUES 768-909
未记录 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.50 Å R-free 0.295
2JH2 X-ray crystal structure of a cohesin-like module from Clostridium perfringens 提交 2007-02-19 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 768–909(142 aa) 片段:RESIDUES 768-909
未记录 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.50 Å R-free 0.295
2JH2 X-ray crystal structure of a cohesin-like module from Clostridium perfringens 提交 2007-02-19 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 768–909(142 aa) 片段:RESIDUES 768-909
未记录 未记录非水小分子 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.50 Å R-free 0.295
2O4E The solution structure of a protein-protein interaction module from a family 84 glycoside hydrolase of Clostridium perfringens 提交 2006-12-04 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 768–909(142 aa) 片段:Putative protein-protein interaction module
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 7;298 K;压力 1
NMR样品组成 1mM U-15N,13C x82, 25mM hepes, 50mM nacl, 5mM cacl2, pH 7.0
分辨率未提供
2OZN The Cohesin-Dockerin Complex of NagJ and NagH from Clostridium perfringens 提交 2007-02-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 768–909(142 aa) 片段:Cohesin module (residues 768-909)
未记录 CL CHLORIDE ION × 1 CA CALCIUM ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 pH 4.5;21% (w/v) polyethylene glycol 2000, 0.2M ammonium sulfate, 100mM sodium acetate, pH 4.5
分辨率 1.60 Å R-free 0.246
2V5C Family 84 glycoside hydrolase from Clostridium perfringens, 2.1 Angstrom structure 提交 2008-10-02 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 31–624(594 aa) 片段:CATALYTIC MODULE, RESIDUES 31-624
未记录 CA CALCIUM ION × 2 CAC CACODYLATE ION × 3 NA SODIUM ION × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.10 Å R-free 0.255
2V5C Family 84 glycoside hydrolase from Clostridium perfringens, 2.1 Angstrom structure 提交 2008-10-02 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 31–624(594 aa) 片段:CATALYTIC MODULE, RESIDUES 31-624
未记录 CA CALCIUM ION × 2 CAC CACODYLATE ION × 2 NA SODIUM ION × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.10 Å R-free 0.255
2V5D Structure of a Family 84 Glycoside Hydrolase and a Family 32 Carbohydrate-Binding Module in Tandem from Clostridium perfringens. 提交 2008-10-02 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 31–767(737 aa) 片段:RESIDUES 31-767
未记录 CA CALCIUM ION × 3 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 3.30 Å R-free 0.370
2VUR Chemical dissection of the link between Streptozotocin, O-GlcNAc and pancreatic cell death 提交 2008-05-29 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 31–624(594 aa) 片段:O-GLCNACASE DOMAIN, RESIDUES 31-624
未记录 YX1 2-deoxy-2-{[(2-hydroxy-1-methylhydrazino)carbonyl]amino}-beta-D-glucopyranose × 1 SO4 SULFATE ION × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.20 Å R-free 0.241
2VUR Chemical dissection of the link between Streptozotocin, O-GlcNAc and pancreatic cell death 提交 2008-05-29 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 31–624(594 aa) 片段:O-GLCNACASE DOMAIN, RESIDUES 31-624
未记录 YX1 2-deoxy-2-{[(2-hydroxy-1-methylhydrazino)carbonyl]amino}-beta-D-glucopyranose × 1 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.20 Å R-free 0.241
2WB5 GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation 提交 2009-02-20 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 31–624(594 aa) 片段:O-GLCNACASE DOMAIN, RESIDUES 31-624
未记录 CL CHLORIDE ION × 2 NA SODIUM ION × 1 VGB (5R,6R,7R,8S)-6,7-dihydroxy-5-(hydroxymethyl)-2-(2-phenylethyl)-8-(propanoylamino)-5,6,7,8-tetrahydro-1H-imidazo[1,2-a]pyridin-4-ium × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 6.5;30% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM COCADYLATE, pH 6.5
分辨率 2.31 Å R-free 0.237
2WB5 GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation 提交 2009-02-20 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 31–624(594 aa) 片段:O-GLCNACASE DOMAIN, RESIDUES 31-624
未记录 CL CHLORIDE ION × 3 VGB (5R,6R,7R,8S)-6,7-dihydroxy-5-(hydroxymethyl)-2-(2-phenylethyl)-8-(propanoylamino)-5,6,7,8-tetrahydro-1H-imidazo[1,2-a]pyridin-4-ium × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 6.5;30% PEG 8000, 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM COCADYLATE, pH 6.5
分辨率 2.31 Å R-free 0.237
2X0Y Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds 提交 2009-12-18 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–624(594 aa) 片段:RESIDUES 31-624
链 B 31–624(594 aa) 片段:RESIDUES 31-624
未记录 X0T 7-[(2S)-2,3-DIHYDROXYPROPYL]-1,3-DIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE × 2 X-RAY DIFFRACTION
X-ray结晶条件 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM CACODYLATE PH 6.5 AND 30 % PEG 8000 AND GAMMA-BUTYROLACTONE
分辨率 2.25 Å R-free 0.246
2XPK Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases 提交 2010-08-26 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–624(594 aa) 片段:RESIDUES 31-624
链 B 31–624(594 aa) 片段:RESIDUES 31-624
突变:YES 突变:YES Z0M N-[(5R,6R,7R,8S)-6,7-DIHYDROXY-5-(HYDROXYMETHYL)-2-(2-PHENYLETHYL)-5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRIDIN-8-YL]-3-SULFANYLPROPANAMIDE × 2 X-RAY DIFFRACTION mmCIF 未提供已读取条件 分辨率 2.40 Å R-free 0.242
2YDQ CpOGA D298N in complex with hOGA-derived O-GlcNAc peptide 提交 2011-03-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–618(588 aa) 片段:RESIDUES 31-618
突变:YES CD CADMIUM ION × 19 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;0.6M NAAC, 0.175M CDSO4, 0.1M HEPES PH 7.5
分辨率 2.60 Å R-free 0.231
2YDR CpOGA D298N in complex with p53-derived O-GlcNAc peptide 提交 2011-03-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–618(588 aa) 片段:RESIDUES 31-618
突变:YES CD CADMIUM ION × 18 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;0.6 M NAAC, 0.175 M CDSO4, 0.1 M HEPES PH 7.5
分辨率 2.75 Å R-free 0.219
2YDS CpOGA D298N in complex with TAB1-derived O-GlcNAc peptide 提交 2011-03-24 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–618(588 aa) 片段:RESIDUES 31-618
突变:YES NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 19 X-RAY DIFFRACTION
X-ray结晶条件 pH 8.5;pH 8.5
分辨率 2.55 Å R-free 0.238
4ZXL CpOGA D298N in complex with Drosophila HCF -derived Thr-O-GlcNAc peptide 提交 2015-05-20 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 39–617(579 aa) 片段:UNP residues 39-617
未记录 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 15 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;295.15 K;CpOGA D298N was concentrated to 35 mg/ml in 25 mM Tris/HCl (pH 8.0) and crystallized from 0.175 M CdSO4 and 0.6 M sodium acetate pH 7.5
分辨率 2.60 Å R-free 0.220
5OXD Complex of a C. perfringens O-GlcNAcase with a fragment hit 提交 2017-09-06 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 31–618(588 aa)
未记录 CD CADMIUM ION × 22 B2W 5-(trifluoromethyl)-2,3-dihydro-1~{H}-1,4-diazepine × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293.15 K;Apo crystals were grown in 0.6 M NaAcetate pH 7.5, 0.175 M cadmium sulphate (ML). Crystals were then transferred into a drop supplemented with 10 mM ligand and incubated for 4 h. Crystals were cryo-protected by short immersion in ML supplemented with 20% glycerol and saturated with ligand.
分辨率 2.60 Å R-free 0.221
6RHE CpOGA D298N in complex with hOGA-derived S-GlcNAc peptide 提交 2019-04-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–619(589 aa)
突变:D298N CD CADMIUM ION × 25 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;1:1 drops of proytein mixed with crystallisation buffer: 0.175 M CdSO4 and 0.6 M NaAc
分辨率 3.10 Å R-free 0.233
7KHV CpOGA IN COMPLEX WITH LIGAND 54 提交 2020-10-22 Assembly 1 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 31–624(594 aa)
链 B 31–624(594 aa)
突变:D298N, V331C, N388D 突变:D298N, V331C, N388D X1A N-(5-{[6-(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-2,6-diazaspiro[3.4]octan-2-yl]methyl}-1,3-thiazol-2-yl)acetamide × 2 CA CALCIUM ION × 1 SO4 SULFATE ION × 11 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 6.6;293 K;2.4M Ammonium Sulfate, 0.1M Hepes
分辨率 2.30 Å R-free 0.247
7KHV CpOGA IN COMPLEX WITH LIGAND 54 提交 2020-10-22 Assembly 2 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 C 31–624(594 aa)
链 D 31–624(594 aa)
突变:D298N, V331C, N388D 突变:D298N, V331C, N388D X1A N-(5-{[6-(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-2,6-diazaspiro[3.4]octan-2-yl]methyl}-1,3-thiazol-2-yl)acetamide × 2 CA CALCIUM ION × 1 SO4 SULFATE ION × 15 CL CHLORIDE ION × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 6.6;293 K;2.4M Ammonium Sulfate, 0.1M Hepes
分辨率 2.30 Å R-free 0.247
7KHV CpOGA IN COMPLEX WITH LIGAND 54 提交 2020-10-22 Assembly 3 蛋白同源多聚体 同源多聚体;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 E 31–624(594 aa)
链 F 31–624(594 aa)
突变:D298N, V331C, N388D 突变:D298N, V331C, N388D X1A N-(5-{[6-(5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-2,6-diazaspiro[3.4]octan-2-yl]methyl}-1,3-thiazol-2-yl)acetamide × 2 CA CALCIUM ION × 1 SO4 SULFATE ION × 9 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;pH 6.6;293 K;2.4M Ammonium Sulfate, 0.1M Hepes
分辨率 2.30 Å R-free 0.247